Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose Intensive Chemotherapy for Children with Malignant Brain Tumors (Head Start II)
NCT00003273Phase 2Withdrawn
- Sponsor
- NYU Langone Health
- Start
- Nov 1997
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands, Covalent Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label trial of thiotepa, etoposide, carboplatin, cisplatin, vincristine and 3 more in brain tumor, medulloblastoma, primitive neuroectodermal tumor (PNET) and 7 more (3 arms), sponsored by NYU Langone Health. Primary endpoints: Toxicity of Induction Chemotherapy and Response Rate to Induction Chemotherapy. Planned start Nov 1997; status: withdrawn.
02
Drugs
thiotepaetoposidecarboplatincisplatinvincristine
03
Conditions
brain tumormedulloblastomaprimitive neuroectodermal tumor (PNET)ependymomaglioblastoma (GBM)
Beyond the preview
Go deeper on NCT00003273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003273.